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Abstract
Background: The combination of artesunate and mefloquine has been reported to be effective against multi-
drug resistant Plasmodium falciparum malaria, which has been reported in Nigeria. The objective of this multi-
centre study was to evaluate the efficacy, safety and tolerability of the co-packaged formulation of artesunate and
mefloquine in the treatment of uncomplicated malaria in two weight groups: those between 15 – 29 kg and ≥ 30
kg respectively.
Methods: The trial was conducted in rural communities in the north-east, north-central, south-west and south-
eastern parts of Nigeria. The WHO protocol for testing antimalarial drugs was followed. Outpatients having
amongst other criteria, parasite density of ≥1,000 μl were enrolled. The co-packaged drugs were administered
for 3 days at a dosage of artesunate, 4 mg/kg body wt/day and mefloquine, 25 mg/kg/body wt total) on days 0, 1
and 2. Patients were followed up for 28 days with the assessment of the parasitological parameters on days 1, 2,
3, 7, and 28.
Results: Four hundred and forty-six (446) patients were enrolled and 431 completed the study. Cure rates in
both treatment groups was >90% at day 28. The mean parasite clearance times in treatment groups I and II were
40.1 and 42.4 hours respectively. The combination of artesunate and mefloquine showed good gametocidal
activity, (gametocyte clearance time of 42.0 & 45.6 hours in treatment groups I and II respectively). There were
no serious adverse events. Other adverse events observed were headache, dizziness, vomiting and abdominal
discomfort. There was no significant derangement in the haematological and biochemical parameters.
Conclusion: This co-packaged formulation of artesunate + mefloquine (Artequin™) is highly efficacious, safe and
well-tolerated. It is recommended for the treatment of uncomplicated P. falciparum malaria in Nigeria.
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Background
Malaria remains one of the greatest causes of morbidity
and mortality in the world. Globally, there are between
300–500 million cases of clinical malaria every year, with
85% of these from Africa [1]. Currently, 1.5 to 2.7 million
deaths are attributable to malaria annually, 90% of them
in Africa [1]. In Nigeria, malaria is holoendemic hence
clinical cases of the disease are seen throughout the year.
It is the commonest cause of outpatient hospital attend-
ance in all age-groups in the country [2]. Under five chil-
dren are especially prone to develop the severe forms of
the disease which, if not treated promptly can lead to
death. Drug Therapeutic Efficacy Tests (DTET) conducted
in different parts of Nigeria on chloroquine and sul-
phadoxine-pyrimethamine combination in 2002 showed
adequate clinical and parasitological response (ACPR) of
39.2% and 56.7% respectively [3]. Thus, chloroquine and
sulphadoxine-pyrimethamine are no longer efficacious in
treating malaria in Nigeria [4,5]. The global malaria con-
trol strategy advocates prompt and adequate treatment
with an effective antimalarial drug as an essential measure
to reduce the morbidity and mortality arising from the
disease [3]. In line with above findings, the Federal Minis-
try of Health considered a change in policy to artemisinin-
based combination therapy (ACT), which has been shown
to be effective in other countries. The rationale for the use
of ACTs is to reduce the probability of resistance develop-
ing simultaneously to two drugs with independent mech-
anisms of action [5,6].
The artemisinin drugs are developed from the Chinese
wormwood (Artemisia annua) and the derivatives, namely,
artemether, artesunate and dihydroartemisinin have now
gained popularity as short acting drugs which could be
used in combination with drugs which have longer half-
life [7,8]. Mefloquine has been reported to consistently
show high treatment efficacy in African children [9,10]
and in pregnant women [11]. This was in the era of anti-
malarial monotherapy. At that time, mefloquine, a 4-qui-
noline carbinol, was reported to be one of the most
effective drugs in the treatment of malaria in Nigeria [12].
It was also found to be an effective suppressive prophylac-
tic drug, when administered weekly or fortnightly against
drug-resistant Plasmodium falciparum [13]. The successful
treatment of falciparum malaria with regimens of artem-
isinin derivatives plus mefloquine has been reported in
other countries [14-17]. The pharmacokinetics of meflo-
quine combined with artesunate in children with acute
falciparum malaria in Thailand has also been studied
[18]. Li et al [19] showed that artesunate has a broader
stage-specificity of action than other antimalarial drugs.
After oral artesunate, relative bioavailability of the drug
was 82.0%. The parasite clearance time (PCT) and fever
clearance time (FCT) were 6.5 hours and 24 hours respec-
tively [20] and parasitaemia was reduced by 90% within
24 hours after starting treatment.
The rationale was based on the convincing evidence that a
combination of two or more schizontocidal drugs will not
only improve cure rate but could help reduce the rate of
development of parasite resistance to either of the drugs in
the combination. Thus, the combination of short-acting
artemisinin derivative (artesunate) with longer acting
mefloquine is expected to constitute a good ACT.
The Drug Therapeutic Efficacy tests (DTET) conducted on
two such combinations, namely, artesunate + amodi-
aquine and artemether + lumefantrine in 2004 showed
adequate clinical and parasitological response (ACPR) of
94.6% and 96.8% respectively [3]. The Federal ministry of
health then changed the policy on malaria treatment to
artemisinin-based combination therapy (ACT) [3].
However, there is the challenge of availability and afford-
ability of ACTs. To improve better access to ACTs at afford-
able prices, Roll Back Malaria partners in the
pharmaceutical industries were encouraged to pre-pack-
age ACTs, which could be used if found effective,
approved and duly registered by the regulatory authori-
ties. One such combination drug is Artequin™, a combina-
tion of artesunate and mefloquine, manufactured by
MEPHA Ltd (Aesch, Basel, Switzerland). Although this
combination has been reported to be efficacious else-
where, there is need to determine the efficacy, safety and
tolerability of this ACT among Nigerians.
This co-packaged formulation of artesunate and meflo-
quine has not been used before now in Nigeria. The out-
come of therapeutic efficacy tests could be different in
Nigeria, or even in different geographic zones of the coun-
try. It is, therefore, important to determine the efficacy,
safety and tolerability of this co-packaged formulation of
AM among Nigerian population. There is also the need to
provide more options for malaria control in Nigeria.
The objectives of the study were:
￿ To evaluate therapeutic efficacy of a combination of
artesunate plus mefloquine (AM) using the modified
WHO seven-day in vivo test extended to 14 and 28 day fol-
low-up period.
￿ To determine the safety and tolerability of AM in the
treatment of acute uncomplicated P. falciparum malaria.
￿ To estimate gametocyte carriage and its reduction during
treatment.Malaria Journal 2008, 7:172 http://www.malariajournal.com/content/7/1/172
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Methods
study design
This was a descriptive, open label, multi-centre, non-com-
parative trial of three-day regimen of a combination of
AM for efficacy, safety and tolerability. Patients were strat-
ified into two treatment groups according to their weights.
Treatment group I consisted of those weighing between
15–29 kg, while treatment group II consisted of partici-
pants whose weight was ≥ 30 kg.
Study sites
This multi-centre study was conducted in four geographi-
cal zones of the country. In southwest Nigeria, 2 health
facilities in Ijede, Lagos were used for the study. Ijede is a
rural community in Ikorodu Local Government Area,
Lagos State. The second site was in Borno, north eastern
Nigeria, where a Specialist Hospital, a General Hospital
and University Teaching Hospital were recruitment
points. The third site was the Primary Health Centre in
Ikot Ansa, Calabar, south eastern Nigeria. The fourth site
was located in north central Nigeria where ECWA Evangel
Hospital, Jos University Teaching Hospital and Plateau
State Specialist Hospital were enrolment points. All sites
were considered to be homogenous and high malaria
transmission areas, hence their suitability for trials of this
nature.
Inclusion criteria
Patients between 15–29 kg or ≥ 30 kg with mono-infec-
tion with a P. falciparum parasitaemia in the range of
1,000 to 250,000 asexual parasites per μl of blood, pres-
ence of axillary temperature ≥37.5°C and/or history of
fever in the preceding 24 hours, informed consent by par-
ent/guardian (in the case of children), ability to come for
the stipulated follow-up visits, and easy access to the
health facility.
Exclusion criteria
Patients with danger signs such as: unable to drink or
breastfeed, unable to sit or stand up, vomiting everything,
recent history of convulsion, lethargic or unconsciousness
were excluded. Others excluded were those with signs of
complicated falciparum malaria, such as severe anaemia
(PCV  ≤ 15%), shock, bleeding disorders, coke colored
urine, jaundice, presence of severe malnutrition by clini-
cal examination and weight for height measurement, his-
tory of allergy to study drugs and pregnant women.
Study procedures
Patients who met the enrolment criteria were recruited.
Written informed consent was obtained prior to enrol-
ment. Day 0 was the day of screening, clinical assessment,
initial malaria smears, haematological and biochemical
assessments and enrolment. Temperature was measured
in the axilla using digital electronic thermometer. Venous
blood was collected from enrolled patients for baseline
laboratory indices. For biochemistry, liver enzymes
(aspartate amino-transferase and alaninie amino-trans-
ferase), total and conjugated bilirubin and serum creati-
nine were done. Haematological parameters such as
haemoglobin, white blood cells (WBC), and erythrocyte
sedimentation rate were also investigated. The patients
were allocated to either treatment group I (15 to 29 kg) or
treatment group II (≥ 30 kg) and given the 3-day co-pack-
aged drug at a dosage of artesunate (4 mg/kg body wt/day,
total = 12 mg/kg) and mefloquine (total = 25 mg/kg body
wt.).
The drugs were administered under supervision and
patients were observed for 60 minutes. If vomiting
occurred within 30 minutes of drug administration, the
full dose was repeated. However, if it occurred 30–60 min-
utes, half the dosage was given again. Participants who
vomited a second time were excluded from the study and
referred for treatment with appropriate parenteral antima-
larial regimen. Use of concomitant medications (includ-
ing acetaminophen) were documented in the Case Report
Form (CRF).
The patients returned on days 1 and 2 to complete the
drug administration and for clinical assessment. They
were also given appointment for days 3, 7, 14 and 28 for
clinical examination and blood smears. They were also
asked to return to the clinic on any other day should they
have new complaints, or any change in their condition.
Patients that failed to report at the health centre for the
scheduled visit were followed to their residence by trial
field workers.
Discontinuation of treatment
Serious adverse events, loss of patient to follow-up, con-
sent withdrawal or withdrawal as a result of treatment fail-
ure, were criteria for discontinuation of treatment.
Efficacy assessments
Primary treatment efficacy was determined based on par-
astological cure rates on days 2, 3, 7, and 28 and by the
times to parasite and fever clearance and from the propor-
tion of patients without gametocytes. The other outcomes
assessed were early treatment failure (ETF), late clinical
failure (LCF) and late parasitological failure (LPF). Recru-
descence denoted clinical recurrence of malaria after the
initial clearance of parasite from circulation. Parasite reap-
pearance after day was interpreted as either true recrudes-
cence or a new infection. Thus, treatment efficacy for cure
rates in our context were described as uncorrected since no
DNA polymerase chain reaction (PCR) analysis was per-
formed in any of the four sites.Malaria Journal 2008, 7:172 http://www.malariajournal.com/content/7/1/172
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Safety assessments
All adverse events were monitored and recorded on the
case report forms (CRFs). Haematological parameters,
liver enzymes and creatinine were assessed for the pur-
pose of detecting abnormal laboratory features that con-
stitute adverse events. Efforts were made to assess patients
that dropped out from the study for the 28 days of active
follow up period for safety reasons.
Sample size calculation
The sample size used for this drug trial was calculated
from the table of anticipated proportion (WHO/HTM/
RBM/2003) at 95% confidence level and 10% precision.
Calculation was based on estimated cure rate for current
artemisinin-based antimalarial drug treatment [3]. With
this combination drug having anticipated proportion of
treatment failure of less than 5%, the sample size for the
trial drug should be 18 (EPI-INFO version 6.04). How-
ever, since a minimum sample size of 50 is recommended
by the World Health Organization (WHO), between 50–
55 patients were enrolled in each treatment group per site
(100 to 110), to adjust for loss to follow up and withdraw-
als.
Data analysis
Data generated from this trial were entered into EPI-INFO
version 6.04. Microsoft excel software was also used to
plot simple graphs. Various aspects of the data were sub-
sequently analysed using SPSS statistical package version
11. Descriptive statistics were produced for different
parameters before figures representing various observa-
tions were compared using X2 or student t-test or analysis
of variance (ANOVA) as appropriate. Pearson's correla-
tion test was used to examine the relationship between
selected variables.
Parasite counts
At screening, thick and thin blood films were collected.
Thick film was examined with a binocular microscope
with an oil immersion objective lens to quantify the para-
sitaemia. Parasitaemia was measured by counting the
number of asexual parasites against a number of leuko-
cytes in the thick blood film, based on a putative count of
8,000 leukocytes per microlitre of blood or an adequate
mean WBC in the population under investigation. The
number of asexual parasites was counted against 200 leu-
kocytes using a hand tally counter. The number of para-
sites per microlitre of blood was calculated by using the
formula:
If P. falciparum gametocytes were seen, a gametocyte count
was performed against 1000 leukocytes (WHO/MAL/
82.988).
Ethical issues
Written approval was obtained by the Ethics Review
Boards (IRBs) of the various institutions for the study. The
Heads of communities and authorities of the various
health facilities also consented to the conduct of the
study. The study was carried out in accordance with the
principles laid down by the World Health Assembly of
1975 on Ethics in Human experimentation and the Hel-
sinki Declaration. The study adhered to Good Clinical
Practices (GCP) and conformed to the TDR Standard
Operating Procedures.
Participants were informed of the aims, methods, antici-
pated benefits and potential hazards of the study. Written
informed consent was obtained from each participant
and/or parent/guardian of patients participating in the
study. Subject were informed that they could withdraw
consent to participate anytime without any consequence
to them. This was written in English and the local dialects
of the various communities.
Results
General
A total of 4,139 patients who had not taken any antima-
larial medication in the previous seven days were screened
in the four sites. Overall, 446 patients fulfilled the criteria
for enrolment and were enrolled, but a total of 431
(96.6%) patients consisting of 203 in treatment group I
(weight ≥ 30 kg) and 228 in treatment group II (weight 15
to 29 kg) completed the study. The demographic and clin-
ical characteristics of the patients are shown in Table 1.
Defaulters
A total of 15 patients defaulted as a result of withdrawal/
loss to follow-up and/or protocol violation. The trial pro-
file is shown in Figure 1.
Efficacy of artesunate+mefloquine
The study outcome of trial participant is shown in table 2
Parasite clearance rate, profile and time
Results showed that on D1, 83(40.9%) of the 203
enrolled treatment group I (TG I) and 72 (31.6%) of the
228 enrolled treatment group II (TG II) no longer had any
malaria parasites in their blood. The mean parasite densi-
ties in the remaining 120 in TG I and 156 in TG II were
drastically reduced. The clearance rate dramatically
increased to 92.1% and 91.7% for TG I and TG II respec-
tively on D2 until total clearance was achieved in the
remaining 16 in TG I and 19 in TG II on D3.
Treatment group I
In treatment group I, the geometric mean parasite density
of the 203 participants enrolled on D0 was 6,890.8 para-
sites/μL of blood, which decreased to 30.74 parasites/μL
on D1, giving a percentage rate of 99.6%. The rates on
Parasite Density  parasites  l
number of parasites   WB 1 μ
− () =
× C C count  8
Number of leukocytes counted  2
000
00
() ∗
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Table 1: Demographic and clinical characteristics of patients at enrolment (Day 0)
Group 1 Weight ≥30 kg Group 2 Characteristics Child Weight 15–29 kg
Sex ratio
Male 78 (38.4%) 139 (61.0%)
Female 125 (61.6%) 89 (39.0%)
Mean age (Yrs) 22.5 ± 11.5 7.1 ± 2.7
Range 9–65 (3–13)
Mean weight (kg) 50.9 ± 14.1 20.5 ± 4.7
Range 30–94 15–29
Mean Parasite Density (μl-1) 19,797.6 ± 33,397.6 27,010.2 ± 35,704.4
Range 1000–220,000 1016 – 235,294
Geometric mean parasite density (μl-1) 6890.8 11,727.5
Mean axillary Temperature (°C)
≥ 37.5°C 38.4 ± 0.75 (n = 94) 38.6 ± 0.79 (n = 132)
Artequin® trial profile in four geographic zones of Nigeria Figure 1
Artequin® trial profile in four geographic zones of Nigeria.Malaria Journal 2008, 7:172 http://www.malariajournal.com/content/7/1/172
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other days (i.e. using the geometric mean parasite densi-
ties) were as follows: D2 (99.98%), D3 (100%), D7
(100%) and D14 (100%). However, on day 28, one of
those in TG I (in Lagos site) manifested low-grade parasite
density of 360 parasite μL-1 blood. It was not possible to
ascertain whether this was recrudescence or of new infec-
tion. It was not possible to confirm recrudescence with
polymerase chain reaction.
Parasite clearance time (PCT) in 203 participants in TG I
was determined from the spread sheet data (WHO/MAL/
82.988). Parasitaemia completely cleared in 83 patients
within 24 hrs, 104 cleared in 48 hrs while 16 patients were
cleared in 72 hours. Time to parasite clearance was calcu-
lated as follows:
Treatment group II
In treatment group II, the geometric mean parasite density
of the 228 enrolled patients on day 0 was 11,727.5 para-
sites/μ of blood which reduced to 54.2 parasites on D1,
giving a percentage rate of 99.2% on D1 (Figure 1). The
rates on the other days, using geometric mean parasite
density, were as follows: D2 (99.97%), D3 (100%), D7
(100%) and D14 (100%). As in TG I, six patients in TG II
in three sites manifested low-grade parasitaemia on day
28. Time to parasite clearance (PCT) in 228 patients in TG
II was also determined from the spread sheet. Here, para-
sitaemia had cleared in 72 patients within 24 hrs (D1),
137 participants within 48 hrs (D 2) and in the remaining
19 within 72 hrs (D3).
Time to parasite clearance was calculated as follows:
Temperature clearance profile
Result showed that 109 of the 203 enrolled patients in
TGI had temperatures below 37.5°C. The mean tempera-
ture of the 94 in TG I patients with temperatures ≥ 37.5°C
was 38.44 ± 0.75°C. The temperature dropped to a mean
value of 36.4 ± 0.67°C in 24 hrs. The mean temperature
of 132 patients in TG II who were febrile (T ≥ 37.5°C) was
38.56 ± 0.79°C. The temperature of these patients
dropped to 36.57 ± 0.81°C by D1 (24 hrs). The fact that
many patients were afebrile pre-treatment made it inap-
propriate to calculate fever clearance time.
Anti-gametocyte activity of artesunate+mefloquine
Three of the four sites investigated the gametocyte carriage
rate and the changes in geometric mean gametocyte den-
sities (GMGD) in the patients. The gametocyte carriage
rate for TG I and TG II were 5.9% and 4.4% respectively.
In ten patients where gametocytes were found, the mean
gametocyte count dropped from pre-treatment levels on
day 1. The gametocytes cleared in four patients in 24
hours, three were cleared in 48 hours and three in 72
hours. Time to gametocyte clearance in TG II was calcu-
lated (as in parasite clearance time) to be 45.6 hours.
In twelve TG I patients where gametocytes were found, the
gametocytes cleared in five patients in 24 hours. It cleared
in four patients in 48 hours and in the remaining three
patients in 72 hours. The gametocyte clearance time in TG
I was 42.0 hours.
Safety and tolerability
No serious adverse event (SAE) was reported during the
study in all the four trial sites. Many adverse events (AE)
of the antimalaria drugs were most likely related to the
underlying malaria disease. Of the 39 reports, 10 patients
(2.3% of total patients treated) reported vomiting. The
others were as follows: headache (9, 2.1%), dizziness (12,
2.8%) and abdominal discomfort (4, 0.9%). There was
one report (0.2%) each of sleeplessness, fast breathing,
weakness and back pain (figure 2.).
Laboratory indices of safety
The result of laboratory characteristics of patients at enrol-
ment is shown in Table 3 and 4. The values in individual
patients varied in accordance with the seriousness of the
infection. However, the mean values of all parameters
() ( ) () ,
.
83 24 104 48 16 72
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8136
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.
72 24 137 48 19 72
228
9672
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Table 2: Study outcome of trial participants
Characteristics/Outcome Group I Group II Group I and II
600/750 mg ≥30 kg 300/375 mg 15 – 30 kg All Participants
Number enrolled 208 238 446
Number completed 203 228 431
Withdrawal/loss to follow up 5(2.5%) 10(4.45) 15(3.5%)
Adequate Clinical and Parasitological Response (ACPR)
Day 28* 202(99.5%) 222(97.4%) 424(97.45%)
Parasite Clearance Time 40.1 hrs 42.4 hrs 41.3
* Not Polymerase chain Reaction (PCR) correctedMalaria Journal 2008, 7:172 http://www.malariajournal.com/content/7/1/172
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were within normal limits on D0. In table 3 the WBC
count showed slight increase in both treatment groups.
The increase was more prominent in the lymphocyte
count with corresponding decrease in neutrophils as treat-
ment progressed.
There was slight decrease in haemoglobin values on day 7
before returning to normal on day 28. All these changes
were not statistically significant (p > 0.05). Other haema-
tological parameters, viz, lymphocytes, neutrophils,
monocytes and eosinophils also had varying values which
were not statistically significant (P > 0.05) from the D0
values (Table 3).
Adverse Events Reported By Study Participants Figure 2
Adverse Events Reported By Study Participants.
Table 3: Haematological Characteristics of Patients on Day 0, 7 and 28
Treatment Group 1 (≥30 kg) Treatment Group 2(15–29 kg)
D0 D7 D28 D0 D7 D28
Hb (mg/L)
Male 11.67 ± 4.12 11.15 ± 2.37 12.19 ± 2.40 10.70 ± 2.65 9.53 ± 2.19 11.56 ± 1.34
Female 11.47 ± 2.49 10.27 ± 1.93 11.45 ± 1.42 10.84 ± 2.99 9.07 ± 3.20 11.58 ± 1.35
ESR 23.79 ± 26.74 14.34 ± 17.23 11.82 ± 14.96 42.73 ± 29.16 18.17 ± 23.66 11.53 ± 13.52
TWBC (× 109/L) 5.27 ± 1.87 5.35 ± 1.93 5.15 ± 1.54 7.25 ± 1.11 5.91 ± 2.50 5.79 ± 4.85
Lymphocytes (× 109/L) 2.22 ± 1.05 2.59 ± 1.09 2.66 ± 1.11 2.87 ± 3.34 2.97 ± 1.69 3.14 ± 3.08
Neutrophils (× 109/L) 2.69 ± 1.28 2.55 ± 1.10 2.33 ± 0.80 4.10 ± 8.01 2.67 ± 1.21 2.47 ± 1.86
Monocytes (× 109/L) 0.24 ± 0.16 0.09 ± 0.08 0.08 ± 0.08 0.09 ± 0.11 0.08 ± 0.08 0.08 ± 0.96
Eosinophils (× 109/L) 0.12 ± 0.14 0.15 ± 0.15 0.09 ± 0.11 0.08 ± 0.11 0.15 ± 0.22 0.10 ± 0.11Malaria Journal 2008, 7:172 http://www.malariajournal.com/content/7/1/172
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The Biochemical values on D0 are also shown in Table 4.
The mean starting values for total bilirubin was 6.16 ±
6.35 μmol-l in TG I and 5.12 ± 5.63 μmol-l in TG II. The
level remained within this value from D0 to D28. There
were also no significant decreases or increases (P > 0.05)
in the values of serum alanine aminotransferase (ALT,
GOT), serum aspartate amonitransferase (AST, GPT) and
alkaline phosphotase (ALK).
Discussion
The therapeutic efficacy study of co-packaged three day
treatment preparation of artesunate and mefloquine in
four different geographic areas of Nigeria showed that the
combination is both effective and well tolerated in the
treatment of acute uncomplicated falciparum malaria.
The geometric mean parasite density was drastically
reduced in both treatment groups within 24 hours after
treatment and completely cleared by day 3 in the remain-
ing patients who completed the study. The parasitological
response in both treatment groups were 100% on D3, D7,
and D14 but 97.5% on day 28. The rapid clinical response
was shown by a drop in temperature to normal values
(viz. below 37.5°C) on the 2nd day. This rapid clinical and
parasitological response confirmed the previous findings
of others [16-19,21,22] who have, for many years worked
in countries where, as in Nigeria, multi-drug-resistant
strains predominate.
Apart from the rapid clearance of asexual forms of P. falci-
parum, AM therapy was also beneficial in inducing signif-
icant reduction in gametocyte rate and density. The data
suggest that AM ultimately cleared gametocytes from
peripheral blood. This shows that AM exhibits a gameto-
cidal effect. The second observation was that patients with
mixed infections of P. falciparum and Plasmodium malariae
were cured parasitologically and clinically.
It was observed in the course of this trial, that parasitae-
mia appeared on day 28 in one patient of the TG I and six
patients of TG II. Parasitaemia was not associated with
fever or other symptoms of malaria. Since analysis of the
parasite genotypes was not performed, it was not possible
to determine whether these were new infections or recru-
descence. It is possible that the observed day 28 parasitae-
mia could be re-infections rather than recrudescence[21].
Falade  et al [23], by genotyping new infections seen
between 2nd and 4th week post-therapy, attributed this
phenomenon to new infections. There is a need to per-
form more molecular genotyping of the parasite strains in
subsequent trials to confirm this observation.
Based on the experience of this study, AM is safe and well-
tolerated. The laboratory values were not significantly dif-
ferent pre-and post-treatment. The marginal variations in
liver function test results may be related to stabilization of
the liver following successful treatment. The same result
was observed with mean haemoglobin values which
returned to normal after recovery. The slight reduction in
mean platelet count (data not presented) was consistent
with the reported findings of relative thrombocytopenia
in 50 to 75% of patients with acute malaria [24].
In conclusion, the results of this study have confirmed the
efficacy of AM in the treatment of P. falciparum malaria in
four sites in Nigeria. It also exhibited significant gameto-
cidal activity. As observed by other workers, the rapid par-
asitological response corresponded to the fast clinical
response.
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Table 4: Biochemical Characteristics of Patients on Day 0, 7 and 28
Treatment Group 1 (> 30 kg) Treatment Group 2 (15–29 kg)
D0 D7 D28 D0 D7 D28
Alkaline Phosphatase (iu/L) 159.55 ± 121.58 156.95 ± 92.51 145.66 ± 99.40 220.64 ± 85.33 181.96 ± 69.98 197.12 ± 86.01
Aspartate amino Transferase (iu/L) 29.12 ± 19.54 21.96 ± 14.54 21.31 ± 16.15 38.58 ± 42.55 21.26 ± 14.21 24.47 ± 21.16
Alanine amino Transferase (iu/L) 20.41 ± 24.94 12.24 ± 10.0 14.23 ± 18.66 23.04 ± 20.40 10.64 ± 9.06 13.17 ± 9.99
Total biribin (μmoi/L) 6.16 ± 6.35 2.80 ± 4.61 4.53 ± 4.42 5.12 ± 5.63 0.95 ± 2.25 4.03 ± 3.59
Conjugated bilirubin (μmoi/L) 2.75 ± 3.25 0.29 ± 0.16 0.27 ± 0.19 0.49 ± 0.58 0.31 ± 0.16 0.38 ± 0.32
Urea 8.96 ± 7.14 8.58 ± 8.90 8.06 ± 8.02 8.22 ± 5.95 8.06 ± 7.43 8.43 ± 7.88
Creatinine 34.12 ± 31.81 38.12 ± 30.55 33.06 ± 91.10 21.97 ± 21.78 24.73 ± 20.92 22.16 ± 20.25Publish with BioMed Central    and   every 
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